Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X:
“What happens to patients with st3 unresectable NSCLC who never receive maintenance IO?
Just out in Clinical Lung our POSITION study:
- N=2,076
- 23% incomplete cCRT (A)
- 12.7% PD within 42d post-cCRT (B)
- mOS A=21.6m, B=10.1m
- Black pts risk for incomplete cCRT
- Vascular/renal disease risk for PD
1 out of 3 patients does not make it to the PACIFIC regimen… Those patients represent an unmet medical need and should enter clinical trials!”
Title: Characterizing Risk Factors and Outcomes in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Experience Progression During/Within 42 Days of Concurrent Chemoradiotherapy: The POSITION Study
Authors: Giannis Mountzios, Julius K. Weng, Eleni Zairi, Kristin Hsieh, Pratibha Chander, William Dunlop, Yao Qiao, Alice Wang, Adam Januszewski
Read the Full Article.
More posts featuring Giannis Mountzios on OncoDaily.
